accountuse for cancer meds is full of potholes. Just witness��the news about Novartis' (NYSE: NOS ) Tasigna��and Afinitor and Pfizer's (NYSE: PFE ) Sutent. Novartis stopped a new trial of Tasigna, approved to treat a type of blood cancer, after it failed to...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Novartis, Pfizer See Cancer Data Questioned
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account